Immunogenicity of a 20-valent pneumococcal conjugate vaccine in adults 18 to 64 years old with medical conditions and other factors that increase risk of pneumococcal disease

The aim of this post hoc analysis was to describe the immunogenicity of the 20-valent pneumococcal conjugate vaccine (PCV20) in adults with chronic medical conditions or smoking that place them at increased risk of developing pneumococcal disease. Data from 2 phase 3, randomized, active-controlled,...

Descripción completa

Detalles Bibliográficos
Autores principales: Sabharwal, Charu, Sundaraiyer, Vani, Peng, Yahong, Moyer, Lisa, Belanger, Todd J., Gessner, Bradford D., Jodar, Luis, Jansen, Kathrin U., Gruber, William C., Scott, Daniel A., Watson, Wendy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2022
Materias:
Pneumococcal – Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9746485/
https://www.ncbi.nlm.nih.gov/pubmed/36368038
http://dx.doi.org/10.1080/21645515.2022.2126253

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9746485/
https://www.ncbi.nlm.nih.gov/pubmed/36368038
http://dx.doi.org/10.1080/21645515.2022.2126253

Ejemplares similares